Global Gastrointestinal 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI01252117

Publication Date:

January 10, 2025

Pages:

118

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Gastrointestinal market size is predicted to grow from US$ 36260 million in 2025 to US$ 44370 million in 2031; it is expected to grow at a CAGR of 3.4% from 2025 to 2031.
Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn"s disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders.
Global Gastrointestinal key players include AstraZeneca, Sanofi, Bayer, Pfizer, GlaxoSmithKline, etc. Global top five manufacturers hold a share over 25%.
Europe is the largest market, with a share about 45%, followed by Asia, and North America, both have a share over 45 percent.
In terms of product, Prescription Gastrointestinal Drug is the largest segment, with a share over 80%. And in terms of application, the largest application is Chronic Gastritis, followed by Peptic Ulcer, etc.
The 鈥淕astrointestinal Industry Forecast鈥� looks at past sales and reviews total world Gastrointestinal sales in 2024, providing a comprehensive analysis by region and market sector of projected Gastrointestinal sales for 2025 through 2031. With Gastrointestinal sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gastrointestinal industry.
This Insight Report provides a comprehensive analysis of the global Gastrointestinal landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Gastrointestinal portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Gastrointestinal market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gastrointestinal and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gastrointestinal.
This report presents a comprehensive overview, market shares, and growth opportunities of Gastrointestinal market by product type, application, key players and key regions and countries.
Segmentation by Type:
Prescription Gastrointestinal Drug
OTC Gastrointestinal Drug
Segmentation by Application:
Chronic Gastritis
Functional Dyspepsia
Peptic Ulcer
Acute Gastroenteritis
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZenec
Sanofi
Bayer
Pfizer
GlaxoSmithKline
Teva
窜别谤颈补锛圱颈濒濒辞迟迟蝉锛�
Perrigo
Boehringer Ingelheim
Purdue Pharma
C.B. Fleet
Abbott
Jiangzhong
Xian-Janssen

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Gastrointestinal 麻豆原创 Size (2020-2031)
2.1.2 Gastrointestinal 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Gastrointestinal by Country/Region (2020, 2024 & 2031)
2.2 Gastrointestinal Segment by Type
2.2.1 Prescription Gastrointestinal Drug
2.2.2 OTC Gastrointestinal Drug
2.3 Gastrointestinal 麻豆原创 Size by Type
2.3.1 Gastrointestinal 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Gastrointestinal 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Gastrointestinal Segment by Application
2.4.1 Chronic Gastritis
2.4.2 Functional Dyspepsia
2.4.3 Peptic Ulcer
2.4.4 Acute Gastroenteritis
2.4.5 Others
2.5 Gastrointestinal 麻豆原创 Size by Application
2.5.1 Gastrointestinal 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Gastrointestinal 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Gastrointestinal 麻豆原创 Size by Player
3.1 Gastrointestinal 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Gastrointestinal Revenue by Player (2020-2025)
3.1.2 Global Gastrointestinal Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Gastrointestinal Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Gastrointestinal by Region
4.1 Gastrointestinal 麻豆原创 Size by Region (2020-2025)
4.2 Global Gastrointestinal Annual Revenue by Country/Region (2020-2025)
4.3 Americas Gastrointestinal 麻豆原创 Size Growth (2020-2025)
4.4 APAC Gastrointestinal 麻豆原创 Size Growth (2020-2025)
4.5 Europe Gastrointestinal 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Gastrointestinal 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Gastrointestinal 麻豆原创 Size by Country (2020-2025)
5.2 Americas Gastrointestinal 麻豆原创 Size by Type (2020-2025)
5.3 Americas Gastrointestinal 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gastrointestinal 麻豆原创 Size by Region (2020-2025)
6.2 APAC Gastrointestinal 麻豆原创 Size by Type (2020-2025)
6.3 APAC Gastrointestinal 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Gastrointestinal 麻豆原创 Size by Country (2020-2025)
7.2 Europe Gastrointestinal 麻豆原创 Size by Type (2020-2025)
7.3 Europe Gastrointestinal 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Gastrointestinal by Region (2020-2025)
8.2 Middle East & Africa Gastrointestinal 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Gastrointestinal 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Gastrointestinal 麻豆原创 Forecast
10.1 Global Gastrointestinal Forecast by Region (2026-2031)
10.1.1 Global Gastrointestinal Forecast by Region (2026-2031)
10.1.2 Americas Gastrointestinal Forecast
10.1.3 APAC Gastrointestinal Forecast
10.1.4 Europe Gastrointestinal Forecast
10.1.5 Middle East & Africa Gastrointestinal Forecast
10.2 Americas Gastrointestinal Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Gastrointestinal Forecast
10.2.2 Canada 麻豆原创 Gastrointestinal Forecast
10.2.3 Mexico 麻豆原创 Gastrointestinal Forecast
10.2.4 Brazil 麻豆原创 Gastrointestinal Forecast
10.3 APAC Gastrointestinal Forecast by Region (2026-2031)
10.3.1 China Gastrointestinal 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Gastrointestinal Forecast
10.3.3 Korea 麻豆原创 Gastrointestinal Forecast
10.3.4 Southeast Asia 麻豆原创 Gastrointestinal Forecast
10.3.5 India 麻豆原创 Gastrointestinal Forecast
10.3.6 Australia 麻豆原创 Gastrointestinal Forecast
10.4 Europe Gastrointestinal Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Gastrointestinal Forecast
10.4.2 France 麻豆原创 Gastrointestinal Forecast
10.4.3 UK 麻豆原创 Gastrointestinal Forecast
10.4.4 Italy 麻豆原创 Gastrointestinal Forecast
10.4.5 Russia 麻豆原创 Gastrointestinal Forecast
10.5 Middle East & Africa Gastrointestinal Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Gastrointestinal Forecast
10.5.2 South Africa 麻豆原创 Gastrointestinal Forecast
10.5.3 Israel 麻豆原创 Gastrointestinal Forecast
10.5.4 Turkey 麻豆原创 Gastrointestinal Forecast
10.6 Global Gastrointestinal Forecast by Type (2026-2031)
10.7 Global Gastrointestinal Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Gastrointestinal Forecast
11 Key Players Analysis
11.1 AstraZenec
11.1.1 AstraZenec Company Information
11.1.2 AstraZenec Gastrointestinal Product Offered
11.1.3 AstraZenec Gastrointestinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 AstraZenec Main Business Overview
11.1.5 AstraZenec Latest Developments
11.2 Sanofi
11.2.1 Sanofi Company Information
11.2.2 Sanofi Gastrointestinal Product Offered
11.2.3 Sanofi Gastrointestinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Sanofi Main Business Overview
11.2.5 Sanofi Latest Developments
11.3 Bayer
11.3.1 Bayer Company Information
11.3.2 Bayer Gastrointestinal Product Offered
11.3.3 Bayer Gastrointestinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Bayer Main Business Overview
11.3.5 Bayer Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Gastrointestinal Product Offered
11.4.3 Pfizer Gastrointestinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Information
11.5.2 GlaxoSmithKline Gastrointestinal Product Offered
11.5.3 GlaxoSmithKline Gastrointestinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 GlaxoSmithKline Main Business Overview
11.5.5 GlaxoSmithKline Latest Developments
11.6 Teva
11.6.1 Teva Company Information
11.6.2 Teva Gastrointestinal Product Offered
11.6.3 Teva Gastrointestinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Teva Main Business Overview
11.6.5 Teva Latest Developments
11.7 窜别谤颈补锛圱颈濒濒辞迟迟蝉锛�
11.7.1 窜别谤颈补锛圱颈濒濒辞迟迟蝉锛� Company Information
11.7.2 窜别谤颈补锛圱颈濒濒辞迟迟蝉锛� Gastrointestinal Product Offered
11.7.3 窜别谤颈补锛圱颈濒濒辞迟迟蝉锛� Gastrointestinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 窜别谤颈补锛圱颈濒濒辞迟迟蝉锛� Main Business Overview
11.7.5 窜别谤颈补锛圱颈濒濒辞迟迟蝉锛� Latest Developments
11.8 Perrigo
11.8.1 Perrigo Company Information
11.8.2 Perrigo Gastrointestinal Product Offered
11.8.3 Perrigo Gastrointestinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Perrigo Main Business Overview
11.8.5 Perrigo Latest Developments
11.9 Boehringer Ingelheim
11.9.1 Boehringer Ingelheim Company Information
11.9.2 Boehringer Ingelheim Gastrointestinal Product Offered
11.9.3 Boehringer Ingelheim Gastrointestinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Boehringer Ingelheim Main Business Overview
11.9.5 Boehringer Ingelheim Latest Developments
11.10 Purdue Pharma
11.10.1 Purdue Pharma Company Information
11.10.2 Purdue Pharma Gastrointestinal Product Offered
11.10.3 Purdue Pharma Gastrointestinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Purdue Pharma Main Business Overview
11.10.5 Purdue Pharma Latest Developments
11.11 C.B. Fleet
11.11.1 C.B. Fleet Company Information
11.11.2 C.B. Fleet Gastrointestinal Product Offered
11.11.3 C.B. Fleet Gastrointestinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 C.B. Fleet Main Business Overview
11.11.5 C.B. Fleet Latest Developments
11.12 Abbott
11.12.1 Abbott Company Information
11.12.2 Abbott Gastrointestinal Product Offered
11.12.3 Abbott Gastrointestinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Abbott Main Business Overview
11.12.5 Abbott Latest Developments
11.13 Jiangzhong
11.13.1 Jiangzhong Company Information
11.13.2 Jiangzhong Gastrointestinal Product Offered
11.13.3 Jiangzhong Gastrointestinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Jiangzhong Main Business Overview
11.13.5 Jiangzhong Latest Developments
11.14 Xian-Janssen
11.14.1 Xian-Janssen Company Information
11.14.2 Xian-Janssen Gastrointestinal Product Offered
11.14.3 Xian-Janssen Gastrointestinal Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Xian-Janssen Main Business Overview
11.14.5 Xian-Janssen Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.